CytoMed Therapeutics Limited Ordinary Shares (GDTC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.90M
Last updated: Nov 17, 2026 at 10:50 AM ET
CytoMed Therapeutics Limited Ordinary Shares (GDTC) Financials: Revenue, Profit and Cash Flow
CytoMed Therapeutics Limited Ordinary Shares reported revenue of SGD 324.39K for the fiscal year ended Dec 31, 2025, up 366.7% from the year before. That year, net income was SGD -3.98M with a net margin of -1227.1%, operating cash flow was SGD -3.70M and free cash flow was SGD -4.40M. The quarter ended Jun 30, 2026 had revenue of SGD 157.29K and net income of SGD -1.77M.
Revenue and Margins
Over the 5 years to Dec 2025, revenue grew from SGD 44.92K, a compound annual rate of 48.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 324.39K | +366.7% | 79.0% | -1476.3% | -1227.1% |
| Dec 2024 | 69.50K | -86.3% | 75.4% | -5175.3% | -3621.1% |
| Dec 2023 | 509.13K | +39.3% | -856.6% | -856.6% | -811.8% |
| Dec 2022 | 365.60K | +334.3% | -29.8% | -640.0% | -856.4% |
| Dec 2021 | 84.18K | +87.4% | 131.0% | -1373.6% | -2463.4% |
| Dec 2020 | 44.92K | N/A | 122.1% | -2955.8% | -4323.2% |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 324.39K | 69.50K | 509.13K | 365.60K | 84.18K | 44.92K | N/A |
| Cost of revenue | 67.99K | 17.12K | 4.36M | 109.04K | 3.50K | 4.63K | N/A |
| Gross profit | 256.39K | 52.38K | -4.36M | -109.04K | 110.29K | 54.84K | N/A |
| Research and development | 2.22M | 1.91M | 1.59M | 1.52M | 1.09M | 1.04M | 439.80K |
| Operating income | -4.79M | -3.60M | -4.36M | -2.34M | -1.16M | -1.33M | -651.88K |
| Net income | -3.98M | -2.52M | -4.13M | -3.13M | -2.07M | -1.94M | -858.75K |
| EBITDA | -3.57M | -2.17M | -3.70M | N/A | N/A | -1.04M | -429.06K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.29K | 189.44K | 168.50K | 205.08K | 134.90K | 134.72K | 141.70K | 112.04K | 112.39K | N/A | 111.96K | 142.25K |
| Gross profit | -2.05M | 165.78K | -2.45M | 173.09K | 125.55K | 125.39K | 127.06K | 110.94K | 111.28K | -38.23K | 110.77K | -63.47K |
| Operating income | -2.05M | -562.07K | -2.45M | -661.11K | -651.54K | -650.70K | -519.00K | -530.23K | -531.87K | -1.52M | -437.61K | -1.58M |
| Net income | -1.77M | -885.23K | -1.74M | -868.35K | -1.13M | -1.12M | -724.93K | -1.10M | -545.63K | -1.46M | -989.17K | -1.08M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of SGD 429.10K by 1.67M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | 7.98M | 10.07M | 12.40M | 5.25M | 6.10M | 3.82M | 2.94M |
| Current assets | 3.66M | 6.00M | 10.12M | 2.51M | 3.29M | 1.47M | 549.01K |
| Cash and equivalents | 2.10M | 4.97M | 9.02M | 1.59M | 2.52M | 887.22K | 374.42K |
| Total liabilities | 1.13M | 1.02M | 1.13M | 4.66M | 3.50M | 3.35M | 1.01M |
| Short-term debt | 60.45K | 45.90K | 40.36K | 3.76M | 2.71M | 2.37M | N/A |
| Long-term debt | 368.66K | 394.31K | 407.77K | 468.83K | 539.12K | 590.67K | N/A |
| Shareholder equity | 6.54M | 8.96M | 11.28M | 589.71K | 2.60M | 477.01K | 1.94M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7.01M | 7.02M | 7.98M | 7.98M | 8.39M | 8.38M | 10.07M | 10.22M | 10.90M | 10.94M | 12.37M | 12.39M |
| Total liabilities | 1.61M | 1.62M | 1.13M | 1.13M | 1.14M | 1.14M | 1.02M | 1.04M | 748.46K | 750.78K | 1.12M | 1.13M |
| Cash and equivalents | 1.46M | 1.46M | 2.10M | 2.10M | 2.87M | 2.86M | 4.97M | 5.05M | 6.47M | 6.49M | 9.00M | 9.01M |
| Shareholder equity | 4.97M | 4.97M | 6.54M | 6.54M | 7.17M | 7.16M | 8.97M | 9.10M | 10.16M | 10.19M | 11.25M | 11.27M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.70M | -2.71M | -3.54M | -1.40M | -1.72M | -916.39K | N/A |
| Capital expenditures | 703.13K | 1.40M | 58.45K | 476.00K | N/A | 245.26K | 1.19M |
| Free cash flow | -4.40M | -4.11M | -3.60M | -1.88M | N/A | -1.16M | N/A |
| Investing cash flow | 929.28K | 1.13M | -2.73M | -475.51K | -825.59K | -492.33K | -1.19M |
| Financing cash flow | 208.65K | -64.88K | 10.92M | 968.35K | 4.18M | 1.91M | 1.20M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.66M | -822.87K | -2.05M | -1.05M | -1.48M | -801.45K | -788.76K | -577.73K | -579.46K | -1.03M | -750.10K | -1.02M |
| Capital expenditures | 186.92K | 93.23K | 297.96K | 145.03K | 335.28K | 174.31K | 248.75K | 454.84K | 456.25K | 30.37K | 20.62K | 8.57K |
| Free cash flow | -1.84M | -916.10K | -2.35M | -1.19M | -1.82M | -975.75K | -1.04M | -1.03M | -1.04M | -1.06M | -770.72K | -1.03M |
Frequently Asked Questions About GDTC
What is CytoMed Therapeutics Limited Ordinary Shares' annual revenue?
CytoMed Therapeutics Limited Ordinary Shares reported revenue of SGD 324.39K for the fiscal year ended Dec 31, 2025.
How fast is CytoMed Therapeutics Limited Ordinary Shares' revenue growing?
Revenue was up 366.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -3.9%.
Is CytoMed Therapeutics Limited Ordinary Shares profitable?
No. CytoMed Therapeutics Limited Ordinary Shares reported net income of SGD -3.98M for the fiscal year ended Dec 31, 2025, with a net margin of -1227.1%.
How much free cash flow does GDTC generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of SGD -3.70M minus capital expenditures of SGD 703.13K produced free cash flow of SGD -4.40M.
How much debt does CytoMed Therapeutics Limited Ordinary Shares have?
The balance sheet dated Dec 31, 2025 reported long-term debt of SGD 368.66K, short-term debt of SGD 60.45K and cash and equivalents of SGD 2.10M.
GDTC pages: Overview, Financials